The best indicator for Clorox (CLX)
We backtested 20 indicators across daily, weekly and hourly charts on real Clorox (CLX) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
Bollinger Mean-Reversion
On the weekly chart, this is the strongest risk-adjusted edge we found for Clorox (CLX) over ~53.5 years — trailing buy-and-hold by 2.7% CAGR.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | Bollinger Mean-Reversion ✓ | Weekly | 5.3% | 0.48 | -28.7% | 80.0% | 35 | -2.7% |
| 2 | EMA 20/50 Cross ✓ | Weekly | 7.3% | 0.44 | -63.7% | 44.4% | 18 | -0.7% |
| 3 | Stochastic ✓ | Daily | 4.7% | 0.35 | -51.9% | 68.1% | 273 | -3.2% |
| 4 | Williams %R ✓ | Daily | 4.6% | 0.34 | -50.0% | 68.2% | 337 | -3.3% |
| 5 | Money Flow Index ✓ | Daily | 4.7% | 0.34 | -80.9% | 74.6% | 59 | -3.3% |
| 6 | WaveTrend (8/6/4) ✓ | Weekly | 4.6% | 0.34 | -73.7% | 83.7% | 43 | -3.4% |
| 7 | RSI Trend (>50) ✓ | Weekly | 4.5% | 0.33 | -63.7% | 46.7% | 152 | -3.5% |
| 8 | Donchian Midline ✓ | Weekly | 4.6% | 0.33 | -61.5% | 54.6% | 141 | -3.4% |
| 9 | Stochastic | Weekly | 4.1% | 0.32 | -73.2% | 74.5% | 51 | -3.9% |
| 10 | Holy Grail Confluence ✓ | Weekly | 3.7% | 0.32 | -75.8% | 86.7% | 15 | -4.3% |
| 11 | EMA 50/200 Cross ✓ | Daily | 4.4% | 0.31 | -66.5% | 42.9% | 42 | -3.6% |
| 12 | Holy Grail Confluence ✓ | Daily | 3.9% | 0.31 | -59.2% | 75.0% | 80 | -4.1% |
| 13 | MACD ✓ | Daily | 3.7% | 0.28 | -58.5% | 41.7% | 530 | -4.2% |
| 14 | EMA-10 Trend ✓ | Weekly | 3.6% | 0.28 | -45.9% | 46.4% | 248 | -4.3% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For Clorox (CLX), Bollinger Mean-Reversion on the weekly timeframe gave the best balance of return and risk in our test. It still trailed buy-and-hold on raw return — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.